CIK 0001540159 · Non-accelerated filer<br>Smaller reporting company
Edesa Biotech, Inc.
Sign in to watch- Ticker
- EDSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (905) 475-1234
- Business address
- C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
- Former names
- Stellar Biotechnologies, Inc.
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Grant or award Chief Executive Officer acquired 3,253 shares (grant or award)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $4.00 ($20,000)
- 4 Grant or award Chief Executive Officer acquired 2,765 shares (grant or award)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Chief Executive Officer acquired 2,978 shares (grant or award)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
- 4 Grant or award Chief Executive Officer acquired 2,908 shares (grant or award)
- 10-K Report Annual Report
- 8-K Event Results of operations
- 8-K Event Other events
- 8-K Event Material agreement · New debt or obligation
- 8-K Event Material agreement · New debt or obligation · Regulation FD disclosure · Other events
- 8-K Event Shareholder rights changed · Other events
- SC 13D/A Stake Beneficial Ownership Report
- 10-Q Report Quarterly Report
Page 9 of 38 · 753 filings